• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    How Investors Are Reacting To Neuren Pharmaceuticals (ASX:NEU) Larger-Than-Expected Phelan-McDermid Syndrome Population Estimate

    Simply Wall St·07/15/2026 10:26:53
    Listen to the news
    • In June 2026, Mount Sinai’s Seaver Autism Center published research in Autism Research estimating Phelan-McDermid syndrome affects about 1 in 7,300 people, a much higher prevalence than earlier thought, in a study supported by CureSHANK and Neuren Pharmaceuticals.
    • This substantially larger patient population estimate highlights a potentially wider addressable market for ongoing precision medicine trials and future therapies targeting Phelan-McDermid syndrome.
    • We’ll now examine how this higher estimated prevalence of Phelan-McDermid syndrome could reshape Neuren Pharmaceuticals’ existing investment narrative.

    Capitalize on the AI infrastructure supercycle with our selection of the 52 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

    Neuren Pharmaceuticals Investment Narrative Recap

    To own Neuren today, you generally need to believe that rare disease neurology, anchored by DAYBUE royalties and NNZ‑2591, can justify a premium valuation despite earnings volatility and partner dependence. The Mount Sinai data suggesting Phelan‑McDermid syndrome is more common materially strengthens the long term addressable market narrative, but it does not immediately change the near term focus on execution by Acadia and regulatory progress for NNZ‑2591, which still look like the key catalyst and primary risk.

    Among recent announcements, the ongoing on‑market share buyback (up to 6,350,631 shares through March 2027) is most relevant here. It signals management’s confidence in Neuren’s financial footing at a time when new prevalence data could support a broader future opportunity set, yet current returns are still heavily linked to DAYBUE performance and milestone timing, so buybacks may amplify both upside and downside around those existing catalysts.

    But while the long term upside case is compelling, the dependence on Acadia and a single commercial product is something investors should be very aware of...

    Read the full narrative on Neuren Pharmaceuticals (it's free!)

    Neuren Pharmaceuticals’ narrative projects A$166.7 million revenue and A$228.4 million earnings by 2028.

    Uncover how Neuren Pharmaceuticals' forecasts yield a A$23.45 fair value, a 34% upside to its current price.

    Exploring Other Perspectives

    ASX:NEU 1-Year Stock Price Chart
    ASX:NEU 1-Year Stock Price Chart

    Some of the most optimistic analysts were already assuming A$239.5 million of revenue and A$140.4 million of earnings by 2028, yet this new prevalence data could either reinforce that view or prompt you to reconsider how much concentration and partner risk you are comfortable with.

    Explore 5 other fair value estimates on Neuren Pharmaceuticals - why the stock might be worth over 6x more than the current price!

    Decide For Yourself

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    • A great starting point for your Neuren Pharmaceuticals research is our analysis highlighting 3 key rewards that could impact your investment decision.
    • Our free Neuren Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Neuren Pharmaceuticals' overall financial health at a glance.

    No Opportunity In Neuren Pharmaceuticals?

    Our daily scans reveal stocks with breakout potential. Don't miss this chance:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.